The first results were presented in 2005 and were the basis for the approval of one year adjuvant treatment of patients with HER2 positive BC.9–11 A significant improvement in disease free survival (DFS) in the range of 40–50% was demonstrated and the risk from dying from BC was reduced by about one third. The gene discussed is ERBB2; the disease is breast cancer.